The pathogenesis of dementia, particularly Alzheimer's disease, is significantly influenced by the central involvement of the amyloid beta (Aβ) protein. Aβ is a naturally occurring fragment derived from the larger amyloid precursor protein (APP). In individuals without cognitive disorders, mechanisms like enzymatic degradation and transport across the blood-brain barrier work to clear Aβ from the brain. However, in those with dementia, Aβ accumulates and forms insoluble plaques in the brain, disrupting neuronal communication and contributing to cognitive decline.
The upcoming Alzheimer's 2024 conference will include a dedicated scientific session on the amyloid beta protein in dementia. This session will delve into the latest research regarding its role in the development of the disease, potential therapeutic targets, and innovative biomarkers for early diagnosis. Experts will explore the mechanisms underlying the accumulation of Aβ and its impact on brain function, presenting findings from clinical trials that investigate anti-amyloid therapies and their potential to alter the progression of the disease.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
